{"id":42533,"date":"2015-09-17T11:25:58","date_gmt":"2015-09-17T16:25:58","guid":{"rendered":"https:\/\/content.findlaw-admin.com\/ability-legal\/contracts\/uncategorized\/marketing-distribution-and-development-agreement-gilead.html"},"modified":"2015-09-17T11:25:58","modified_gmt":"2015-09-17T16:25:58","slug":"marketing-distribution-and-development-agreement-gilead","status":"publish","type":"corporate_contracts","link":"https:\/\/corporate.findlaw.com\/contracts\/operations\/marketing-distribution-and-development-agreement-gilead.html","title":{"rendered":"Marketing, Distribution and Development Agreement – Gilead Sciences Inc. and Cubist Pharmaceuticals Inc."},"content":{"rendered":"
 MARKETING, DISTRIBUTION AND DEVELOPMENT AGREEMENT  <\/b><\/p>\n\n
 BY AND BETWEEN  <\/b><\/p>\n\n
 GILEAD SCIENCES, INC.  <\/b><\/p>\n\n
 AND  <\/b><\/p>\n\n
 CUBIST PHARMACEUTICALS, INC.  <\/b><\/p>\n\n
 January 6, 2001  <\/b><\/p>\n\n
[*]=CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH \nTHE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.  <\/b><\/p>\n\n
\n\n\n
 <\/a>  TABLE OF CONTENTS  <\/b><\/p>\n\n\n<\/pre>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
<\/th>\n <\/th>\n<\/th>\n <\/th>\nPAGE<\/b><\/p>\n
<\/th>\n<\/tr>\n
ARTICLE 1<\/td>\n <\/td>\nDEFINITIONS<\/td>\n <\/td>\n1<\/td>\n<\/tr>\n
 <\/td>\n1.1<\/td>\n <\/td>\n“Affiliate”<\/td>\n <\/td>\n1<\/td>\n<\/tr>\n
 <\/td>\n1.2<\/td>\n <\/td>\n“Bacteremia”<\/td>\n <\/td>\n1<\/td>\n<\/tr>\n
 <\/td>\n1.3<\/td>\n <\/td>\n“CAP”<\/td>\n <\/td>\n1<\/td>\n<\/tr>\n
 <\/td>\n1.4<\/td>\n <\/td>\n“Change in Control”<\/td>\n <\/td>\n1<\/td>\n<\/tr>\n
 <\/td>\n1.5<\/td>\n <\/td>\n“Clinical Transfer Price”<\/td>\n <\/td>\n1<\/td>\n<\/tr>\n
 <\/td>\n1.6<\/td>\n <\/td>\n“Commercial Launch”<\/td>\n <\/td>\n1<\/td>\n<\/tr>\n
 <\/td>\n1.7<\/td>\n <\/td>\n“Commercialize”<\/td>\n <\/td>\n1<\/td>\n<\/tr>\n
 <\/td>\n1.8<\/td>\n <\/td>\n“Commercially Reasonable Efforts”<\/td>\n <\/td>\n2<\/td>\n<\/tr>\n
 <\/td>\n1.9<\/td>\n <\/td>\n“Compulsory License”<\/td>\n <\/td>\n2<\/td>\n<\/tr>\n
 <\/td>\n1.10<\/td>\n <\/td>\n“Confidential Information”<\/td>\n <\/td>\n2<\/td>\n<\/tr>\n
 <\/td>\n1.11<\/td>\n <\/td>\n“Control”<\/td>\n <\/td>\n2<\/td>\n<\/tr>\n
 <\/td>\n1.12<\/td>\n <\/td>\n“Core IV Products”<\/td>\n <\/td>\n2<\/td>\n<\/tr>\n
 <\/td>\n1.13<\/td>\n <\/td>\n“Core Licensed Products”<\/td>\n <\/td>\n2<\/td>\n<\/tr>\n
 <\/td>\n1.14<\/td>\n <\/td>\n“Core Trials”<\/td>\n <\/td>\n2<\/td>\n<\/tr>\n
 <\/td>\n1.15<\/td>\n <\/td>\n“CPMP”<\/td>\n <\/td>\n2<\/td>\n<\/tr>\n
 <\/td>\n1.16<\/td>\n <\/td>\n“cSST”<\/td>\n <\/td>\n2<\/td>\n<\/tr>\n
 <\/td>\n1.17<\/td>\n <\/td>\n“Cubist Development Plan”<\/td>\n <\/td>\n2<\/td>\n<\/tr>\n
 <\/td>\n1.18<\/td>\n <\/td>\n“Cubist Diligence Obligation”<\/td>\n <\/td>\n2<\/td>\n<\/tr>\n
 <\/td>\n1.19<\/td>\n <\/td>\n“Cubist Know-How”<\/td>\n <\/td>\n2<\/td>\n<\/tr>\n
 <\/td>\n1.20<\/td>\n <\/td>\n“Cubist Marks”<\/td>\n <\/td>\n2<\/td>\n<\/tr>\n
 <\/td>\n1.21<\/td>\n <\/td>\n“Cubist Patent”<\/td>\n <\/td>\n2<\/td>\n<\/tr>\n
 <\/td>\n1.22<\/td>\n <\/td>\n“Cubist Technology”<\/td>\n <\/td>\n2<\/td>\n<\/tr>\n
 <\/td>\n1.23<\/td>\n <\/td>\n“cUTI”<\/td>\n <\/td>\n2<\/td>\n<\/tr>\n
 <\/td>\n1.24<\/td>\n <\/td>\n“Daptomycin”<\/td>\n <\/td>\n3<\/td>\n<\/tr>\n
 <\/td>\n1.25<\/td>\n <\/td>\n“Daptomycin Product”<\/td>\n <\/td>\n3<\/td>\n<\/tr>\n
 <\/td>\n1.26<\/td>\n <\/td>\n“Daptomycin-Derived Product”<\/td>\n <\/td>\n3<\/td>\n<\/tr>\n
 <\/td>\n1.27<\/td>\n <\/td>\n“Development Subcommittee”<\/td>\n <\/td>\n3<\/td>\n<\/tr>\n
 <\/td>\n1.28<\/td>\n <\/td>\n“Diligence Obligation”<\/td>\n <\/td>\n3<\/td>\n<\/tr>\n
 <\/td>\n1.29<\/td>\n <\/td>\n“Directly Competitive Product”<\/td>\n <\/td>\n3<\/td>\n<\/tr>\n
 <\/td>\n1.30<\/td>\n <\/td>\n“Dollar”<\/td>\n <\/td>\n3<\/td>\n<\/tr>\n
 <\/td>\n1.31<\/td>\n <\/td>\n“Drug Approval Application”<\/td>\n <\/td>\n3<\/td>\n<\/tr>\n
 <\/td>\n1.32<\/td>\n <\/td>\n“EC”<\/td>\n <\/td>\n3<\/td>\n<\/tr>\n
 <\/td>\n1.33<\/td>\n <\/td>\n“EMEA”<\/td>\n <\/td>\n3<\/td>\n<\/tr>\n
 <\/td>\n1.34<\/td>\n <\/td>\n“Endocarditis”<\/td>\n <\/td>\n3<\/td>\n<\/tr>\n
 <\/td>\n1.35<\/td>\n <\/td>\n“Enterococcal Infection”<\/td>\n <\/td>\n3<\/td>\n<\/tr>\n
 <\/td>\n1.36<\/td>\n <\/td>\n“FDA”<\/td>\n <\/td>\n3<\/td>\n<\/tr>\n
 <\/td>\n1.37<\/td>\n <\/td>\n“Force Majeure<\/td>\n <\/td>\n3<\/td>\n<\/tr>\n
 <\/td>\n1.38<\/td>\n <\/td>\n“Free Sales Certificate”<\/td>\n <\/td>\n3<\/td>\n<\/tr>\n
 <\/td>\n1.39<\/td>\n <\/td>\n“Gilead Development Plan”<\/td>\n <\/td>\n4<\/td>\n<\/tr>\n
 <\/td>\n1.40<\/td>\n <\/td>\n‘Gilead Diligence Obligation”<\/td>\n <\/td>\n4<\/td>\n<\/tr>\n
 <\/td>\n1.41<\/td>\n <\/td>\n“Gilead Indemnifiable Technology”<\/td>\n <\/td>\n4<\/td>\n<\/tr>\n
 <\/td>\n1.42<\/td>\n <\/td>\n“Gilead Indemnifiable Technology Losses”<\/td>\n <\/td>\n4<\/td>\n<\/tr>\n
 <\/td>\n1.43<\/td>\n <\/td>\n“Gilead Marks”<\/td>\n <\/td>\n4<\/td>\n<\/tr>\n
 <\/td>\n1.44<\/td>\n <\/td>\n“Gilead Project Know-How”<\/td>\n <\/td>\n4<\/td>\n<\/tr>\n
 <\/td>\n1.45<\/td>\n <\/td>\n“Gilead Project Patent”<\/td>\n <\/td>\n4<\/td>\n<\/tr>\n
 <\/td>\n1.46<\/td>\n <\/td>\n“Gilead Project Technology”<\/td>\n <\/td>\n4<\/td>\n<\/tr>\n<\/table>\n
i<\/p>\n
\n
 <\/a><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
 <\/td>\n1.47<\/td>\n <\/td>\n“Gilead Territory”<\/td>\n <\/td>\n4<\/td>\n<\/tr>\n
 <\/td>\n1.48<\/td>\n <\/td>\n“HAP”<\/td>\n <\/td>\n4<\/td>\n<\/tr>\n
 <\/td>\n1.49<\/td>\n <\/td>\n“Incremental Product Development Costs”<\/td>\n <\/td>\n4<\/td>\n<\/tr>\n
 <\/td>\n1.50<\/td>\n <\/td>\n“IND”<\/td>\n <\/td>\n4<\/td>\n<\/tr>\n
 <\/td>\n1.51<\/td>\n <\/td>\n“Information”<\/td>\n <\/td>\n4<\/td>\n<\/tr>\n
 <\/td>\n1.52<\/td>\n <\/td>\n“Infringement”<\/td>\n <\/td>\n4<\/td>\n<\/tr>\n
 <\/td>\n1.53<\/td>\n <\/td>\n“IV Product”<\/td>\n <\/td>\n4<\/td>\n<\/tr>\n
 <\/td>\n1.54<\/td>\n <\/td>\n“Joint Invention”<\/td>\n <\/td>\n5<\/td>\n<\/tr>\n
 <\/td>\n1.55<\/td>\n <\/td>\n“Joint Patent”<\/td>\n <\/td>\n5<\/td>\n<\/tr>\n
 <\/td>\n1.56<\/td>\n <\/td>\n“Licensed Product”<\/td>\n <\/td>\n5<\/td>\n<\/tr>\n
 <\/td>\n1.57<\/td>\n <\/td>\n“Lilly”<\/td>\n <\/td>\n5<\/td>\n<\/tr>\n
 <\/td>\n1.58<\/td>\n <\/td>\n“Lilly License”<\/td>\n <\/td>\n5<\/td>\n<\/tr>\n
 <\/td>\n1.59<\/td>\n <\/td>\n“Loss”<\/td>\n <\/td>\n5<\/td>\n<\/tr>\n
 <\/td>\n1.60<\/td>\n <\/td>\n“MAA”<\/td>\n <\/td>\n5<\/td>\n<\/tr>\n
 <\/td>\n1.61<\/td>\n <\/td>\n“Marketing Subcommittee”<\/td>\n <\/td>\n5<\/td>\n<\/tr>\n
 <\/td>\n1.62<\/td>\n <\/td>\n“MSL”<\/td>\n <\/td>\n5<\/td>\n<\/tr>\n
 <\/td>\n1.63<\/td>\n <\/td>\n“NDA”<\/td>\n <\/td>\n5<\/td>\n<\/tr>\n
 <\/td>\n1.64<\/td>\n <\/td>\n“Necessary”<\/td>\n <\/td>\n5<\/td>\n<\/tr>\n
 <\/td>\n1.65<\/td>\n <\/td>\n“Net Sales”<\/td>\n <\/td>\n5<\/td>\n<\/tr>\n
 <\/td>\n1.66<\/td>\n <\/td>\n“Oral Product”<\/td>\n <\/td>\n6<\/td>\n<\/tr>\n
 <\/td>\n1.67<\/td>\n <\/td>\n“Oral Product Fee”<\/td>\n <\/td>\n6<\/td>\n<\/tr>\n
 <\/td>\n1.68<\/td>\n <\/td>\n“Other Licensee”<\/td>\n <\/td>\n6<\/td>\n<\/tr>\n
 <\/td>\n1.69<\/td>\n <\/td>\n“Patent”<\/td>\n <\/td>\n6<\/td>\n<\/tr>\n
 <\/td>\n1.70<\/td>\n <\/td>\n“Permitted Sublicense”<\/td>\n <\/td>\n6<\/td>\n<\/tr>\n
 <\/td>\n1.71<\/td>\n <\/td>\n“Phase I Clinical Trial”<\/td>\n <\/td>\n6<\/td>\n<\/tr>\n
 <\/td>\n1.72<\/td>\n <\/td>\n“Phase II Clinical Trial”<\/td>\n <\/td>\n6<\/td>\n<\/tr>\n
 <\/td>\n1.73<\/td>\n <\/td>\n“Phase III Clinical Trials”<\/td>\n <\/td>\n6<\/td>\n<\/tr>\n
 <\/td>\n1.74<\/td>\n <\/td>\n“Phase IIIB Clinical Trials”<\/td>\n <\/td>\n6<\/td>\n<\/tr>\n
 <\/td>\n1.75<\/td>\n <\/td>\n“Phase IV Clinical Trials”<\/td>\n <\/td>\n6<\/td>\n<\/tr>\n
 <\/td>\n1.76<\/td>\n <\/td>\n“Price Approval”<\/td>\n <\/td>\n7<\/td>\n<\/tr>\n
 <\/td>\n1.77<\/td>\n <\/td>\n“Primary Endpoint”<\/td>\n <\/td>\n7<\/td>\n<\/tr>\n
 <\/td>\n1.78<\/td>\n <\/td>\n“Refund Event”<\/td>\n <\/td>\n7<\/td>\n<\/tr>\n
 <\/td>\n1.79<\/td>\n <\/td>\n“Regulatory Approval”<\/td>\n <\/td>\n7<\/td>\n<\/tr>\n
 <\/td>\n1.80<\/td>\n <\/td>\n“Regulatory Authority”<\/td>\n <\/td>\n7<\/td>\n<\/tr>\n
 <\/td>\n1.81<\/td>\n <\/td>\n“Related Gilead Know-How”<\/td>\n <\/td>\n7<\/td>\n<\/tr>\n
 <\/td>\n1.82<\/td>\n <\/td>\n“Related Gilead Project Patent”<\/td>\n <\/td>\n7<\/td>\n<\/tr>\n
 <\/td>\n1.83<\/td>\n <\/td>\n“Related Gilead Technology”<\/td>\n <\/td>\n7<\/td>\n<\/tr>\n
 <\/td>\n1.84<\/td>\n <\/td>\n“ROFR Territory”<\/td>\n <\/td>\n7<\/td>\n<\/tr>\n
 <\/td>\n1.85<\/td>\n <\/td>\n“Steering Committee”<\/td>\n <\/td>\n7<\/td>\n<\/tr>\n
 <\/td>\n1.86<\/td>\n <\/td>\n“Supply Agreement”<\/td>\n <\/td>\n7<\/td>\n<\/tr>\n
 <\/td>\n1.87<\/td>\n <\/td>\n“Term”<\/td>\n <\/td>\n7<\/td>\n<\/tr>\n
 <\/td>\n1.88<\/td>\n <\/td>\n“Third Party Royalties”<\/td>\n <\/td>\n7<\/td>\n<\/tr>\n
 <\/td>\n1.89<\/td>\n <\/td>\n“Third Party”<\/td>\n <\/td>\n7<\/td>\n<\/tr>\n
 <\/td>\n1.90<\/td>\n <\/td>\n“Transfer Price”<\/td>\n <\/td>\n7<\/td>\n<\/tr>\n
 <\/td>\n1.91<\/td>\n <\/td>\n“Valid Claim”<\/td>\n <\/td>\n7<\/td>\n<\/tr>\n
ARTICLE 2<\/td>\n <\/td>\nMANAGEMENT<\/td>\n <\/td>\n8<\/td>\n<\/tr>\n
 <\/td>\n2.1<\/td>\n <\/td>\nGeneral<\/td>\n <\/td>\n8<\/td>\n<\/tr>\n
 <\/td>\n2.2<\/td>\n <\/td>\nSteering Committee<\/td>\n <\/td>\n8<\/td>\n<\/tr>\n
 <\/td>\n2.3<\/td>\n <\/td>\nFormation of Subcommittees<\/td>\n <\/td>\n9<\/td>\n<\/tr>\n
 <\/td>\n2.4<\/td>\n <\/td>\nProject Coordinators<\/td>\n <\/td>\n11<\/td>\n<\/tr>\n<\/table>\n
ii<\/p>\n
\n
 <\/a><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
 <\/td>\n2.5<\/td>\n <\/td>\nCollaboration Guidelines<\/td>\n <\/td>\n11<\/td>\n<\/tr>\n
 <\/td>\n2.6<\/td>\n <\/td>\nAccounting<\/td>\n <\/td>\n11<\/td>\n<\/tr>\n
ARTICLE 3<\/td>\n <\/td>\nDEVELOPMENT<\/td>\n <\/td>\n11<\/td>\n<\/tr>\n
 <\/td>\n3.1<\/td>\n <\/td>\nCubist Development, Development Plan, and Diligence Obligation<\/td>\n <\/td>\n11<\/td>\n<\/tr>\n
 <\/td>\n3.2<\/td>\n <\/td>\nGilead Development Plan<\/td>\n <\/td>\n13<\/td>\n<\/tr>\n
 <\/td>\n3.3<\/td>\n <\/td>\nResponsibilities of the Development Subcommittee during Development<\/td>\n <\/td>\n13<\/td>\n<\/tr>\n
 <\/td>\n3.4<\/td>\n <\/td>\nModification of Clinical Trials; Incremental Product Development Costs<\/td>\n <\/td>\n13<\/td>\n<\/tr>\n
 <\/td>\n3.5<\/td>\n <\/td>\nDetermination of Cubist Diligence<\/td>\n <\/td>\n14<\/td>\n<\/tr>\n
ARTICLE 4<\/td>\n <\/td>\nREGULATORY<\/td>\n <\/td>\n15<\/td>\n<\/tr>\n
 <\/td>\n4.1<\/td>\n <\/td>\nGeneral<\/td>\n <\/td>\n15<\/td>\n<\/tr>\n
 <\/td>\n4.2<\/td>\n <\/td>\nFree Sales Certificates; Ownership of Regulatory Approvals<\/td>\n <\/td>\n15<\/td>\n<\/tr>\n
 <\/td>\n4.3<\/td>\n <\/td>\nGilead Access to Cubist and Other Licensee Information<\/td>\n <\/td>\n16<\/td>\n<\/tr>\n
 <\/td>\n4.4<\/td>\n <\/td>\nCubist and Other Licensee Access to Gilead Information<\/td>\n <\/td>\n17<\/td>\n<\/tr>\n
 <\/td>\n4.5<\/td>\n <\/td>\nAdverse Event Reporting<\/td>\n <\/td>\n17<\/td>\n<\/tr>\n
 <\/td>\n4.6<\/td>\n <\/td>\nCommunications<\/td>\n <\/td>\n17<\/td>\n<\/tr>\n
 <\/td>\n4.7<\/td>\n <\/td>\nApplications for Regulatory Exclusivity<\/td>\n <\/td>\n17<\/td>\n<\/tr>\n
 <\/td>\n4.8<\/td>\n <\/td>\nRecalls and Voluntary Withdrawals<\/td>\n <\/td>\n17<\/td>\n<\/tr>\n
 <\/td>\n4.9<\/td>\n <\/td>\nLabel<\/td>\n <\/td>\n18<\/td>\n<\/tr>\n
ARTICLE 5<\/td>\n <\/td>\nCOMMERCIALIZATION; DILIGENCE<\/td>\n <\/td>\n19<\/td>\n<\/tr>\n
 <\/td>\n5.1<\/td>\n <\/td>\nRight<\/td>\n <\/td>\n19<\/td>\n<\/tr>\n
 <\/td>\n5.2<\/td>\n <\/td>\nResponsibilities of the Marketing Subcommittee during Commercialization<\/td>\n <\/td>\n19<\/td>\n<\/tr>\n
 <\/td>\n5.3<\/td>\n <\/td>\nMarketing Plan<\/td>\n <\/td>\n19<\/td>\n<\/tr>\n
 <\/td>\n5.4<\/td>\n <\/td>\nActivities by MSLs in Gilead Territory<\/td>\n <\/td>\n19<\/td>\n<\/tr>\n
 <\/td>\n5.5<\/td>\n <\/td>\nDiligence Obligation<\/td>\n <\/td>\n20<\/td>\n<\/tr>\n
 <\/td>\n5.6<\/td>\n <\/td>\nDetermination of Gilead’s Diligence<\/td>\n <\/td>\n21<\/td>\n<\/tr>\n
 <\/td>\n5.7<\/td>\n <\/td>\nDiversion of Resources for Directly Competitive Product<\/td>\n <\/td>\n21<\/td>\n<\/tr>\n
 <\/td>\n5.8<\/td>\n <\/td>\nDiscounting<\/td>\n <\/td>\n22<\/td>\n<\/tr>\n
 <\/td>\n5.9<\/td>\n <\/td>\nGilead Compliance<\/td>\n <\/td>\n22<\/td>\n<\/tr>\n
ARTICLE 6<\/td>\n <\/td>\nLICENSE; RIGHTS OF FIRST REFUSAL; EXCLUSIVITY<\/td>\n <\/td>\n22<\/td>\n<\/tr>\n
 <\/td>\n6.1<\/td>\n <\/td>\nPatent Licenses to Gilead<\/td>\n <\/td>\n22<\/td>\n<\/tr>\n
 <\/td>\n6.2<\/td>\n <\/td>\nPatent Licenses to Cubist<\/td>\n <\/td>\n22<\/td>\n<\/tr>\n
 <\/td>\n6.3<\/td>\n <\/td>\nNonexclusive Know-How License to Gilead<\/td>\n <\/td>\n23<\/td>\n<\/tr>\n
 <\/td>\n6.4<\/td>\n <\/td>\nNonexclusive Know-How License to Cubist<\/td>\n <\/td>\n23<\/td>\n<\/tr>\n
 <\/td>\n6.5<\/td>\n <\/td>\nRights of First Refusal and Negotiation<\/td>\n <\/td>\n23<\/td>\n<\/tr>\n
 <\/td>\n6.6<\/td>\n <\/td>\nExclusivity<\/td>\n <\/td>\n24<\/td>\n<\/tr>\n
 <\/td>\n6.7<\/td>\n <\/td>\nTrademark License<\/td>\n <\/td>\n24<\/td>\n<\/tr>\n
 <\/td>\n6.8<\/td>\n <\/td>\nThird Party Technology<\/td>\n <\/td>\n25<\/td>\n<\/tr>\n
 <\/td>\n <\/td>\n(a) Required<\/td>\n <\/td>\n25<\/td>\n<\/tr>\n
 <\/td>\n <\/td>\n(b) Desirable<\/td>\n <\/td>\n25<\/td>\n<\/tr>\n
 <\/td>\n6.9<\/td>\n <\/td>\nSublicensed Technology<\/td>\n <\/td>\n25<\/td>\n<\/tr>\n
 <\/td>\n6.10<\/td>\n <\/td>\nRelated Gilead Technology.<\/td>\n <\/td>\n26<\/td>\n<\/tr>\n
 <\/td>\n6.11<\/td>\n <\/td>\nSublicensing<\/td>\n <\/td>\n26<\/td>\n<\/tr>\n
 <\/td>\n6.12<\/td>\n <\/td>\nUse of Patents and Know-How<\/td>\n <\/td>\n26<\/td>\n<\/tr>\n
 <\/td>\n6.13<\/td>\n <\/td>\nField<\/td>\n <\/td>\n26<\/td>\n<\/tr>\n
ARTICLE 7<\/td>\n <\/td>\nMANUFACTURE AND SUPPLY<\/td>\n <\/td>\n26<\/td>\n<\/tr>\n
 <\/td>\n7.1<\/td>\n <\/td>\nSupply by Cubist<\/td>\n <\/td>\n26<\/td>\n<\/tr>\n
 <\/td>\n7.2<\/td>\n <\/td>\nTransfer Price<\/td>\n <\/td>\n27<\/td>\n<\/tr>\n
ARTICLE 8<\/td>\n <\/td>\nCOMPENSATION<\/td>\n <\/td>\n28<\/td>\n<\/tr>\n
 <\/td>\n8.1<\/td>\n <\/td>\nLicense Fee<\/td>\n <\/td>\n28<\/td>\n<\/tr>\n
 <\/td>\n8.2<\/td>\n <\/td>\nMilestone Payments<\/td>\n <\/td>\n28<\/td>\n<\/tr>\n<\/table>\n
iii<\/p>\n
\n
 <\/a><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
 <\/td>\n8.3<\/td>\n <\/td>\nRoyalties<\/td>\n <\/td>\n29<\/td>\n<\/tr>\n
 <\/td>\n8.4<\/td>\n <\/td>\nTerm of Royalties<\/td>\n <\/td>\n30<\/td>\n<\/tr>\n
 <\/td>\n8.5<\/td>\n <\/td>\nThird Party Royalties and Other Payments<\/td>\n <\/td>\n30<\/td>\n<\/tr>\n
 <\/td>\n8.6<\/td>\n <\/td>\nRoyalty Payments and Reports<\/td>\n <\/td>\n30<\/td>\n<\/tr>\n
 <\/td>\n8.7<\/td>\n <\/td>\nTaxes<\/td>\n <\/td>\n30<\/td>\n<\/tr>\n
 <\/td>\n8.8<\/td>\n <\/td>\nBlocked Currency<\/td>\n <\/td>\n30<\/td>\n<\/tr>\n
 <\/td>\n8.9<\/td>\n <\/td>\nForeign Exchange<\/td>\n <\/td>\n30<\/td>\n<\/tr>\n
 <\/td>\n8.10<\/td>\n <\/td>\nPayments to or Reports by Affiliates<\/td>\n <\/td>\n31<\/td>\n<\/tr>\n
 <\/td>\n8.11<\/td>\n <\/td>\nLate Payments.<\/td>\n <\/td>\n31<\/td>\n<\/tr>\n
ARTICLE 9<\/td>\n <\/td>\nINTELLECTUAL PROPERTY<\/td>\n <\/td>\n31<\/td>\n<\/tr>\n
 <\/td>\n9.1<\/td>\n <\/td>\nOwnership of Inventions<\/td>\n <\/td>\n31<\/td>\n<\/tr>\n
 <\/td>\n9.2<\/td>\n <\/td>\nProsecution of Patents<\/td>\n <\/td>\n31<\/td>\n<\/tr>\n
 <\/td>\n9.3<\/td>\n <\/td>\nPatent Term Extensions.<\/td>\n <\/td>\n32<\/td>\n<\/tr>\n
 <\/td>\n9.4<\/td>\n <\/td>\nNon-Patent Regulatory Exclusivity<\/td>\n <\/td>\n32<\/td>\n<\/tr>\n
 <\/td>\n9.5<\/td>\n <\/td>\nInfringement of Patents by Third Parties<\/td>\n <\/td>\n32<\/td>\n<\/tr>\n
 <\/td>\n9.6<\/td>\n <\/td>\nInfringement of Third Party Rights<\/td>\n <\/td>\n34<\/td>\n<\/tr>\n
 <\/td>\n9.7<\/td>\n <\/td>\nRoyalty Reduction<\/td>\n <\/td>\n35<\/td>\n<\/tr>\n
 <\/td>\n9.8<\/td>\n <\/td>\nPatent Marking<\/td>\n <\/td>\n35<\/td>\n<\/tr>\n
 <\/td>\n9.9<\/td>\n <\/td>\nSelection and Registration of Product Trademarks<\/td>\n <\/td>\n35<\/td>\n<\/tr>\n
 <\/td>\n9.10<\/td>\n <\/td>\nInfringement of Trademarks by Third Parties<\/td>\n <\/td>\n36<\/td>\n<\/tr>\n
 <\/td>\n9.11<\/td>\n <\/td>\nPatent Oppositions<\/td>\n <\/td>\n36<\/td>\n<\/tr>\n
 <\/td>\n <\/td>\n(a) Third Party Patent Rights<\/td>\n <\/td>\n36<\/td>\n<\/tr>\n
 <\/td>\n <\/td>\n(b) Parties’ Patent Rights<\/td>\n <\/td>\n36<\/td>\n<\/tr>\n
 <\/td>\n <\/td>\n(c) Noncontravention<\/td>\n <\/td>\n36<\/td>\n<\/tr>\n
 <\/td>\n9.12<\/td>\n <\/td>\nLilly License<\/td>\n <\/td>\n36<\/td>\n<\/tr>\n
ARTICLE 10<\/td>\n <\/td>\nREPRESENTATIONS AND WARRANTIES<\/td>\n <\/td>\n36<\/td>\n<\/tr>\n
 <\/td>\n10.1<\/td>\n <\/td>\nMutual Representations and Warranties<\/td>\n <\/td>\n36<\/td>\n<\/tr>\n
 <\/td>\n10.2<\/td>\n <\/td>\nCubist<\/td>\n <\/td>\n37<\/td>\n<\/tr>\n
 <\/td>\n10.3<\/td>\n <\/td>\nDisclaimer<\/td>\n <\/td>\n38<\/td>\n<\/tr>\n
 <\/td>\n10.4<\/td>\n <\/td>\nNo Other Representations<\/td>\n <\/td>\n38<\/td>\n<\/tr>\n
ARTICLE 11<\/td>\n <\/td>\nINDEMNIFICATION<\/td>\n <\/td>\n38<\/td>\n<\/tr>\n
 <\/td>\n11.1<\/td>\n <\/td>\nIndemnification by Cubist<\/td>\n <\/td>\n38<\/td>\n<\/tr>\n
 <\/td>\n11.2<\/td>\n <\/td>\nIndemnification by Gilead<\/td>\n <\/td>\n38<\/td>\n<\/tr>\n
 <\/td>\n11.3<\/td>\n <\/td>\nProcedure<\/td>\n <\/td>\n38<\/td>\n<\/tr>\n
 <\/td>\n11.4<\/td>\n <\/td>\nInsurance<\/td>\n <\/td>\n39<\/td>\n<\/tr>\n
 <\/td>\n11.5<\/td>\n <\/td>\nNo Application to Third Party Infringement Claims<\/td>\n <\/td>\n39<\/td>\n<\/tr>\n
 <\/td>\n11.6<\/td>\n <\/td>\nLimitation of Liability<\/td>\n <\/td>\n39<\/td>\n<\/tr>\n
ARTICLE 12<\/td>\n <\/td>\nRECORDS; PUBLICATIONS<\/td>\n <\/td>\n39<\/td>\n<\/tr>\n
 <\/td>\n12.1<\/td>\n <\/td>\nRecords<\/td>\n <\/td>\n39<\/td>\n<\/tr>\n
 <\/td>\n12.2<\/td>\n <\/td>\nPublications<\/td>\n <\/td>\n40<\/td>\n<\/tr>\n
ARTICLE 13<\/td>\n <\/td>\nCONFIDENTIALITY<\/td>\n <\/td>\n40<\/td>\n<\/tr>\n
 <\/td>\n13.1<\/td>\n <\/td>\nTreatment of Confidential Information<\/td>\n <\/td>\n40<\/td>\n<\/tr>\n
 <\/td>\n13.2<\/td>\n <\/td>\nAuthorized Disclosure<\/td>\n <\/td>\n41<\/td>\n<\/tr>\n
 <\/td>\n13.3<\/td>\n <\/td>\nPublicity<\/td>\n <\/td>\n41<\/td>\n<\/tr>\n
ARTICLE 14<\/td>\n <\/td>\nTERM AND TERMINATION<\/td>\n <\/td>\n41<\/td>\n<\/tr>\n
 <\/td>\n14.1<\/td>\n <\/td>\nTerm<\/td>\n <\/td>\n41<\/td>\n<\/tr>\n
 <\/td>\n14.2<\/td>\n <\/td>\nTermination by Gilead<\/td>\n <\/td>\n41<\/td>\n<\/tr>\n
 <\/td>\n14.3<\/td>\n <\/td>\nTermination for Breach<\/td>\n <\/td>\n42<\/td>\n<\/tr>\n
 <\/td>\n14.4<\/td>\n <\/td>\nCubist Rights upon Certain Terminations of the Agreement or as to Certain Licensed Products<\/td>\n <\/td>\n42<\/td>\n<\/tr>\n<\/table>\n
iv<\/p>\n
\n
 <\/a><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
 <\/td>\n14.5<\/td>\n <\/td>\nGilead Rights upon Certain Terminations<\/td>\n <\/td>\n43<\/td>\n<\/tr>\n
 <\/td>\n14.6<\/td>\n <\/td>\nSurvival<\/td>\n <\/td>\n43<\/td>\n<\/tr>\n
 <\/td>\n14.7<\/td>\n <\/td>\nClarification with respect to Supply Agreement.<\/td>\n <\/td>\n43<\/td>\n<\/tr>\n
 <\/td>\n14.8<\/td>\n <\/td>\nRepurchase of Inventory<\/td>\n <\/td>\n43<\/td>\n<\/tr>\n
ARTICLE 15<\/td>\n <\/td>\nDISPUTE RESOLUTION<\/td>\n <\/td>\n44<\/td>\n<\/tr>\n
 <\/td>\n15.1<\/td>\n <\/td>\nDisputes<\/td>\n <\/td>\n44<\/td>\n<\/tr>\n
 <\/td>\n15.2<\/td>\n <\/td>\nGoverning Law; Judicial Resolution<\/td>\n <\/td>\n44<\/td>\n<\/tr>\n
 <\/td>\n15.3<\/td>\n <\/td>\nPatent and Trademark Dispute Resolution<\/td>\n <\/td>\n44<\/td>\n<\/tr>\n
 <\/td>\n15.4<\/td>\n <\/td>\n[*] Resolution of Certain Disputes<\/td>\n <\/td>\n44<\/td>\n<\/tr>\n
ARTICLE 16<\/td>\n <\/td>\nMISCELLANEOUS<\/td>\n <\/td>\n45<\/td>\n<\/tr>\n
 <\/td>\n16.1<\/td>\n <\/td>\nEntire Agreement; Amendment<\/td>\n <\/td>\n45<\/td>\n<\/tr>\n
 <\/td>\n16.2<\/td>\n <\/td>\nForce Majeure<\/td>\n <\/td>\n45<\/td>\n<\/tr>\n
 <\/td>\n16.3<\/td>\n <\/td>\nNotices<\/td>\n <\/td>\n45<\/td>\n<\/tr>\n
 <\/td>\n16.4<\/td>\n <\/td>\nMaintenance of Records<\/td>\n <\/td>\n46<\/td>\n<\/tr>\n
 <\/td>\n16.5<\/td>\n <\/td>\nNo Strict Construction<\/td>\n <\/td>\n46<\/td>\n<\/tr>\n
 <\/td>\n16.6<\/td>\n <\/td>\nAssignment<\/td>\n <\/td>\n46<\/td>\n<\/tr>\n
 <\/td>\n16.7<\/td>\n <\/td>\nPerformance by Affiliates<\/td>\n <\/td>\n46<\/td>\n<\/tr>\n
 <\/td>\n16.8<\/td>\n <\/td>\nCounterparts<\/td>\n <\/td>\n47<\/td>\n<\/tr>\n
 <\/td>\n16.9<\/td>\n <\/td>\nFurther Actions<\/td>\n <\/td>\n47<\/td>\n<\/tr>\n
 <\/td>\n16.10<\/td>\n <\/td>\nSeverability<\/td>\n <\/td>\n47<\/td>\n<\/tr>\n
 <\/td>\n16.11<\/td>\n <\/td>\nHeadings<\/td>\n <\/td>\n47<\/td>\n<\/tr>\n
 <\/td>\n16.12<\/td>\n <\/td>\nNo Waiver<\/td>\n <\/td>\n47<\/td>\n<\/tr>\n<\/table>\n
v<\/p>\n
\n
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO
\nRULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.  <\/b><\/p>\n
 MARKETING, DISTRIBUTION AND DEVELOPMENT AGREEMENT  <\/b><\/p>\n
    THIS MARKETING, DISTRIBUTION AND DEVELOPMENT AGREEMENT<\/b> (the “Agreement”) is made effective as of the 6th day of
\nJanuary, 2001 (the “Effective Date”) by and between GILEAD SCIENCES, INC.,<\/b> a Delaware corporation having its principal place of business at 333
\nLakeside Drive, Foster City, CA 94404 (“Gilead”), and CUBIST PHARMACEUTICALS, INC.<\/b>, a Delaware corporation having its principal place of business
\nat 24 Emily Street, Cambridge, Massachusetts 02139 (“Cubist”). Cubist and Gilead are sometimes referred to herein individually as a “Party” and collectively as the “Parties”, and references to
\n“Gilead” and “Cubist” shall include their respective Affiliates. <\/p>\n
RECITALS  <\/b><\/p>\n
    WHEREAS<\/b>, Cubist has in-licensed and continues to develop a proprietary compound known under the
\ngeneric name of daptomycin; <\/p>\n
    WHEREAS<\/b>, Cubist is currently conducting clinical trials of an intravenous formulation of daptomycin for the treatment of various
\ngram-positive bacterial infections in humans, and is evaluating an oral formulation of daptomycin in preclinical studies; <\/p>\n
    WHEREAS<\/b>, Gilead possesses extensive capabilities in the development, promotion and marketing of anti-infective
\npharmaceutical products in Europe and desires to seek regulatory approval for and market daptomycin in Europe; and <\/p>\n
    WHEREAS<\/b>, Gilead desires to obtain the exclusive right to develop and commercialize daptomycin in the European Community and certain
\nadditional countries, and Cubist desires to grant Gilead such rights in such countries all as set forth below; <\/p>\n
    NOW THEREFORE<\/b>, based on the foregoing premises and the mutual covenants and obligations set forth below, the Parties agree as follows: <\/p>\n
 <\/a>
\n <\/a>
\n
ARTICLE 1
  DEFINITIONS    
  <\/b><\/p>\n
    The following terms shall have the following meanings as used in this Agreement: <\/p>\n
    1.1 “Affiliate”<\/b> shall mean, except as provided below, an entity that, directly or indirectly, through one or more
\nintermediaries, controls, is controlled by or is under common control with Cubist or Gilead. <\/p>\n
    1.2 “Bacteremia”<\/b> shall mean the treatment of a blood-borne infection caused by any bacteria. <\/p>\n
    1.3 “CAP”<\/b> shall mean the treatment of community acquired pneumonia. <\/p>\n
    1.4 “Change in Control”<\/b> shall mean that a Third Party shall have become the beneficial owner of securities representing  [*]<\/b> or more of the aggregate voting power
\nof the then outstanding voting securities of Cubist, or any sale by Cubist of all or
\nsubstantially all of Cubist’s assets. <\/p>\n
    1.5 “Clinical Transfer Price”<\/b> shall have the meaning assigned such term in Section 7.2. <\/p>\n
    1.6 “Commercial Launch”<\/b> shall mean the first sale of a Licensed Product to a Third Party in a given country. <\/p>\n
    1.7 “Commercialize”<\/b> shall have the meaning assigned such term in Section 5.1 and “Commercialization” shall be
\ninterpreted accordingly. <\/p>\n
\n
 <\/a><\/p>\n
\n    1.8 “Commercially Reasonable Efforts”<\/b> shall mean, with respect to a Party’s obligation under this Agreement to develop
\nor commercialize Licensed Product, the level of efforts required to carry out such obligation in sustained manner consistent with the efforts a similarly situated biopharmaceutical company devotes to
\na product of similar market potential, profit potential or strategic value resulting from its own research efforts, based on conditions then prevailing. <\/p>\n
    1.9 “Compulsory License”<\/b> shall mean a compulsory license under any Cubist Patent obtained by a Third Party through the
\norder, decree, or grant of a governmental authority of competent jurisdiction, authorizing such Third Party to manufacture, use, sell, offer for sale or import a product competitive with a Licensed
\nProduct in one or more countries within the Gilead Territory. <\/p>\n
    1.10 “Confidential Information”<\/b> shall mean all Information, and other information and materials, received by either
\nParty from the other Party pursuant to this Agreement, other than that portion of such information or materials which: <\/p>\n